Drug targeting strategies in cancer treatment: An overview

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 1, 2011, Pages 1-17

  Arias, J L ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Active targeting; Antitumor activity; Cancer treatment; Chemotherapy agent; Colloidal drug delivery systems; Controlled release; Drug carrier; Nanotoxicity; Passive targeting

Indexed keywords

DOXORUBICIN; FLUOROURACIL; FOLATE RECEPTOR; GENEXOL PM; GONADORELIN; IMMUNOLIPOSOME; LIGAND; METHOTREXATE; MONTMORILLONITE; NANOCARRIER; PACLITAXEL; PLURONIC F 108; POLOXAMER; RETASPIMYCIN; SMALL INTERFERING RNA; TAMOXIFEN; TRANSFERRIN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; DRUG TUMOR LEVEL; GLIOMA; HUMAN; LIPOSOMAL DELIVERY; LIVER TOXICITY; MULTIDRUG RESISTANCE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOSTRUCTURES; NEOPLASMS;

EID: 78650910950     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955711793564024     Document Type: Article

References (159)

1. Zhang, D.Y.; Shen, X.Z.; Wang, J.Y.; Dong, L.; Zheng, Y.L.; Wu, L.L. Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice. World J. Gastroenterol., 2008, 14, 3554-3562.
2. Jain, R.K. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J. Control.Release, 2001, 74, 7-25.
3. Reddy, L.H. Drug delivery to tumors: recent strategies. J. Pharm. Pharmacol., 2005, 57, 1231-1242.
4. Arias, J.L. Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems. Molecules, 2008, 13, 2340-2369.
5. Durán, J.D.G.; Arias, J.L.; Gallardo, V.; Delgado, A.V. Magnetic colloids as drug vehicles. J. Pharm. Sci., 2008, 97, 2948-2983.
6. Davis, M.E.; Chen, Z.; Shin, D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Dicov.,2008, 7, 771-782.
7. Cho, K.; Wang, X.; Nie, S.; Chen, Z.; Shin, D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res., 2008,14, 1310-1316.
8. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev.,2001, 53, 283-318.
9. Blagoeva, P.M.; Balansky, R.M.; Mircheva, T.J.; Simeonova, M.I. Diminished genotoxicity of mitomycin C and famorubicin included in polybutylcyanoacrylate nanoparticles. Mutat. Res., 1992, 268, 77-82.
10. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 2002, 54, 631-651.
11. Gu, F.X.; Karnik, R.; Wang, A.Z.; Alexis, F.; Levy-Nissenbaum, E.; Hong, S.; Langer, R.S.; Farokhzad, O.C. Targeted nanoparticles for cancer therapy. Nano Today, 2007, 2, 14-21.
12. Maeda, H.; Bharate, G.Y.; Daruwalla, J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J.Pharm. Biopharm., 2009, 71, 409-419.
13. Mitra, S.; Gaur, U.; Gosh, P.C.; Maitra, A.N. Tumor targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Release, 2001, 74, 317-323.
14. Couvreur, P.; Vauthier, C. Nanotechnology: Intelligent design to treat complex disease. Pharm. Res., 2006, 23, 1417-1450.
15. Decuzzi, P.; Pasqualini, R.; Arap, W.; Ferrari, M. Intravascular delivery of particulate systems: Does geometry really matter?Pharm. Res., 2009, 26, 235-243.
16. Rapoport, N. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Prog. Polym. Sci., 2007, 32, 962-990.
17. Moghimi, S.M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res., 2003, 42, 463-478.
18. Park, J.W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res., 2002, 4, 95-99.
19. Zara, G.P.; Cavalli, R.; Bargoni, A.; Fundaro, A.; Vighetto, D.; Gasco, M.R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target., 2002, 10, 327-335.
20. Huwyler, J.; Drewe, J.; Krähenbühl, S. Tumor targeting using liposomal antineoplastic drugs. Int. J. Nanomed., 2008, 3, 21-29.
21. Allen, T.M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci., 1994, 15, 215-220.
22. Hau, P.; Fabel, K.; Baumgart, U.; Rummele, P.; Grauer, O.; Bock, A.; Dietmaier, C.; Dietmaier, W.; Dietrich, J.; Dudel, C.; Hübner, F.; Jauch, T.; Drechsel, E.; Kleiter, I.; Wismeth, C.; Zellner, A.; Brawanski, A.; Steinbrecher, A.; Marienhagen, J.; Bogdahn, U. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer, 2004, 100, 1199-1207.
23. Shenoy, D.B.; Amiji, M.M. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int. J. Pharm., 2005, 293, 261-270.
24. Patil, Y.B.; Toti, U.S.; Khdair, A.; Ma, L.; Panyam, J. Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials, 2009, 30, 859-866.
25. Jeong, Y.I.; Seo, S.J.; Park, I.K.; Lee, H.C.; Kang, I.C.; Akaike, T.; Cho, C.S. Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(gamma-benzyl L-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int. J. Pharm., 2005, 296, 151-161.
26. Park, J.W.; Kirpotin, D.B.; Hong, K.; Shalaby, R.; Shao, Y.; Nielsen, U.B.; Marks, J.D.; Papahadjopoulus, D.; Benz, C.C. Anti-HER2 immunoliposomes: enhanced anticancer efficacy due to targeted delivery. J. Control. Release, 2001, 74, 95-113.
27. Park, J.W.; Hong, K.; Kirpotin, D.B.; Colbern, G.; Shalaby, R.; Baselga, J.; Shao, Y.; Nielsen, U.B.; Marks, J.D.; Moore, D.; Papahadjopoulus, D.; Benz, C.C. Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 2002, 8, 1172-1181.
28. Hood, J.D.; Bednarski, M.; Frausto, R.; Guccione, S.; Reisfeld, R.A.; Xiang, R.; Cheresh, D.A. Tumor regression by targeted gene delivery to the neovasculature. Science, 2002, 296, 2404-2407.
29. Lu, Y.J.; Low, P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev., 2002, 54, 675-693.
30. Imai, K.; Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer, 2006, 6, 714-727.
31. Sapra, P.; Allen, T.M. Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res., 2003, 42, 439-462.
32. Maruyama, K.; Takizawa, T.; Yuda, T.; Kennel, S.J.; Huang, L.; Iwatsuru, M. Targetability of novel immunoliposomes modified with amphipatic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal-antibodies. Biochim. Biophys. Acta, 1995, 1234, 74-80.
33. Gao, J.; Zhonga, W.; Hea, J.; Li, H.; Zhanga, H.; Zhoua, G.; Li, B.; Lua, Y.; Zoua, H.; Koua, G.; Zhanga, D.; Wanga, H.; Guoa, Y.; Zhong, Y. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. Int. J. Pharm., 2009, 374, 145-152.
34. Zhang, Y.; Schlachetzki, F.; Pardridge, W.M. Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther., 2003, 7, 11-18.
35. Kos, J.; Obermajer, N.; Doljaka, B.; Kocbeka, P.; Kristl, J. Inactivation of harmful tumour-associated proteolysis by nanoparticulate system. Int. J. Pharm., 2009, 381, 106-112.
36. Sun, B.; Ranganathan, B.; Feng, S.S. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials, 2008, 29, 475-486.
37. Hallahan, D.; Geng, L.; Qu, S.; Scarfone, C.; Giorgio, T.; Donnelly, E.; Gao, X.; Clanton, J. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell, 2003, 63, 363-374.
38. Schiffelers, R.M.; Koning, G.A.; ten Hagen, T.L.; Fens, M.H.; Schraa, A.J.; Janssen, A.P.; Kok, R.J.; Molema, G.; Strom, G. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release, 2003, 91, 115-122.
39. Bibby, D.C.; Talmadge, J.E.; Dalal, M.K.; Kurz, S.G.; Chytil, K.M.; Barry, S.E.; Shand, D.G.; Steiert, M. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int. J. Pharm., 2005, 293, 281-290.
40. Karmali, P.P.; Kotamraju, V.R.; Kastantin, M.; Black, M.; Missirlis, D.; Tirrell, M.; Ruoslahti, E. Targeting of albuminembedded paclitaxel nanoparticles to tumors. Nanomedicine: NBM, 2009, 5, 73-82.
41. Garg, A.; Tisdale, A.W.; Haidari, E.; Kokkoli, E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int. J. Pharm., 2009, 366, 201-210.
42. Mai, J.; Song, S.; Rui, M.; Liu, D.; Ding, Q.; Peng, J.; Xu, Y. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cellsJ. Control. Release, 2009, 139, 174-181.
43. Taratula, O.; Garbuzenko, O.B.; Kirkpatrick, P.; Pandya, I.; Savla, R.; Pozharov, V.P.; He, H.; Minko, T. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J. Control. Release, 2009, 140, 284-293.
44. Veiseh, O.; Kievit, F.M.; Gunn, J.W.; Ratner, B.D.; Zhang, M. A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials, 2009, 30, 649-657.
45. Önyüksel, H.; Mohantya, P.S.; Rubinsteina, I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17- demethoxy geldanamycin: A novel targeted nanomedicine for breast cancer. Int. J. Pharm., 2009, 365, 157-161.
46. Guan, H.; McGuire, M.J.; Li, S.; Brown, K.C. Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of alpha(v)beta(6)-positive cancers. Bioconjug. Chem., 2008, 19, 1813-1821.
47. Willis, M.C.; Collins, B.D.; Zhang, T.; Green, L.S.; Sebesta, D.P.; Bell, C.; Kellogg, E.; Gill, S.C.; Magallanez, A.; Knauer, S.; Bendele, R.A.; Gill, P.S.; Janjic, N.; Collins, B. Liposomeanchored vascular endothelial growth factor aptamers. Bioconjug. Chem., 1998, 9, 573-582.
48. Levy-Nissenbaum, E.; Radovic-Moreno, A.F.; Wang, A.Z.; Langer, R.; Farokhzad, O.C. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol., 2008, 26, 442-449.
49. Farokhzad, O.C.; Cheng, J.; Teply, B.A.; Sherifi, I.; Jon, S.; Kantoff, P.W.; Richie, J.P.; Langer, R. Targeted nanoparticleaptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA, 2006, 103, 6315-6320.
50. Lai, T.Y.; Lee, W.C. Killing of cancer cell line by photoexcitation of folic acid-modified titanium dioxide nanoparticles. J. Photochem. Photobiol. A: Chem., 2009, 204, 148-153.
51. Low, P.S.; Kularatne, S.A. Folate-targeted therapeutic and imaging agents for cancer. Curr. Opin. Chem. Biol., 2009, 13, 256-262.
52. Pan, J.; Feng, S.S. Targeting and imaging cancer cells by Folatedecorated, quantum dots (QDs)- loaded nanoparticles of biodegradable polymers. Biomaterials, 2009, 30, 1176-1183.
53. Gabizon, A.; Shmeeda, H.; Horowitz, A.T.; Zalipsky, S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev., 2004, 56, 1177-1192.
54. Shmeeda, H.; Mak, L.; Tzemach, D.; Astrahan, P.; Tarshish, M.; Gabizon, A. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with upregulated folate receptors. Mol. Cancer Ther., 2006, 5, 818-824.
55. Pan, X.Q.; Lee, R.J. In vivo antitumor activity of folate receptortargeted liposomal daunorubicin in a murine leukemia model. Anticancer Res., 2005, 25, 343-346.
56. Goren, D.; Horowitz, A.T.; Tzemach, D.; Tarshish, M.; Zalipsky, S.; Gabizon, A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res., 2000, 6, 1949-1957.
57. Gerasimov, O.V.; Boomer, J.A.; Qualls, M.M.; Thompson, D.H. Cytosolic drug delivery using pH- and light-sensitive liposomes. Adv. Drug Deliv. Rev., 1999, 38, 317-338.
58. Esmaeili, F.; Grahremani, M.H.; Ostad, S.N.; Atyabi, F.; Seyedabadi, M.; Malekshahi, M.R.; Amini, M.; Dinarvand, R. Folate-receptor-targeting delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J. Drug Target., 2008, 16, 415-423.
59. Kim, S.H.; Jeong, J.H.; Chun, K.W.; Park, T.G. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)- poly(ethylene glycol)-folate conjugate. Langmuir, 2005, 21, 8852-8857.
60. Stevens, P.J.; Sekido, M.; Lee, R.J. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm. Res., 2004, 21, 2153-2157.
61. Liang, B.; He, M.L.; Chan, C.Y.; Chen, Y.C.; Li, X.P.; Li, Y.; Zheng, D.; Lin, M.C.; Kung, H.F.; Shuai, X.T.; Peng, Y. The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat. Biomaterials, 2009, 30, 4014-4020.
62. Stella, B.; Arpicco, S.; Peracchia, M.T.; Desmaële, D.; Hoebeke, J.; Rendir, M.; d́Angelo, J.;Cattel, L.; Couvreur, P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci., 2000, 89, 1452-1464.
63. Park, E.K.; Lee, S.B.; Lee, Y.M. Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials, 2005, 26, 1053-1061.
64. Derycke, A.; Kamuhabwa, A.; Gijsens, A.; Roskams, T.; de Vos, D.; Kasran, A.; Huwyler, J.; Missiaen, L.; de Witte, P.A.M. Transferrin-conjugated liposome targeting of the photosensitizer AlPcS4 to rat bladder carcinoma cells. J. Natl. Cancer Inst., 2004, 96, 1620-1630.
65. Hwang, S.H.; Rait, A.; Pirollo, K.F.; Zhou, Q.; Yenugonda, V.M.; Chinigo, G.M.; Brown, M.L.; Chang, E.H. Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue. Mol. Cancer. Ther., 2008, 7, 559-568.
66. Lemieux, P.; Page, M. Sensitivity of multidrug-resistant MCF-7 cells to a transferrin-doxorubicin conjugate. Anticancer Res., 1994, 14, 397-403.
67. Singh, M.; Atwal, H.; Micetich, R. Transferrin directed delivery of adriamycin to human cells. Anticancer Res., 1998, 18, 1423-1427.
68. Sahoo, S.K.; Ma, W.; Labhasetwar, V. Efficacy of transferrinconjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer, 2004, 112, 335-340.
69. Sahoo, S.K.; Labhasetwar, V. Enhanced antiproliferative activity of transferrin conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol. Pharm., 2005, 2, 373-383.
70. Pardridge, W.M. Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Adv. Exp. Med. Biol., 2002, 513, 397-430.
71. Li, J.L.; Wang, L.; Liu, X.Y.; Zhang, Z.P.; Guo, H.C.; Liu, W.M.; Tang, S.H. In vitro cancer cell imaging and therapy using transferring-conjugated gold nanoparticles. Cancer Lett., 2009, 274, 319-326.
72. Bawa, P.; Pillay, V.; Choonara, Y.E.; Toif, L.C. Stimuli-responsive polymers and their applications in drug delivery. Biomed. Mater., 2009, 4, 022001.
73. Ulbrich, K.; ubr, V. Polymeric anticancer drugs with pHcontrolled activation. Adv. Drug Deliv. Rev., 2004, 56, 1023-1050.
74. Stubbs, M.; McSheehy, R.M.J.; Griffiths, J.R.; Bashford, L. Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today, 2000, 6, 15-19.
75. Hilgenbrink, A.R.; Low, P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci., 2005, 94, 2135-2146.
76. Jeong, J.H.; Kim, S.W.; Park, T.G. A new antisense oligonucleotide delivery system based on self-assembled ODNPEG hybrid conjugate micelles. J. Control. Release, 2003, 93, 183-191.
77. Lo, C.L.; Lin, K.M.; Hsiue, G.H. Preparation and characterization of intelligent core-shell nanoparticles based on poly(D,L-lactide)-gpoly(N-isopropyl acrylamide-comethacrylic acid). J. Control. Release, 2005, 104, 477-488.
78. Han, S.K.; Na, K.; Bae, Y.H. Sulfonamide based pH sensitive polymeric micelles: physicochemical characteristics and pHdependent aggregation. Colloids Surf. A Physicochem. Eng. Aspects, 2003, 214, 49-59.
79. Na, K.; Lee, E.S.; Bae, Y.H. Adryamicin loaded pullulan acetate/sulfonamide conjugate nanoparticles responding to tumor pH: pH-dependent cell interaction, internalization and cytotoxicity in vitro. J. Control. Release, 2003, 87, 3-13.
80. Kamada, H.; Tsutsumi, Y.; Yoshioka, Y.; Yamamoto, Y.; Kodaira, H.; Tsunoda, S.; Okamoto, T.; Mukai, Y.; Shibata, H.; Nakagawa, S.; Mayumi, T. Design of a pH-sensitive polymeric carrier for drug release and its application in cancer therapy. Clin. Cancer Res., 2004, 10, 2545-2550.
81. Kim, D.; Lee, E.S.; Park, K.; Kwon, I.C.; Bae, Y.H. Doxorubicin loaded pH-sensitive micelle: antitumoral efficacy against ovarian A2780/DOXR tumor Pharm. Res., 2008, 25, 2074-2082.
82. Li, F.; Wu, H.; Zhang, H.; Li, F.; Gu, C.H.; Yang, Q. Antitumor drug Paclitaxel-loaded pH-sensitive nanoparticles targeting tumor extracellular pH. Carbohydr. Polym., 2009, 77, 773-778.
83. Krakovičová, H.; Etrych, T.; Ulbrich, K. HPMA-based polymer conjugates with drug combination. Eur. J. Pharm. Sci., 2009, 37, 405-412.
84. Karanth, H.; Murthy, R.S. pH-sensitive liposomes: principle and application in cancer therapy J. Pharm. Pharmacol., 2007, 59, 469-483.
85. Kim, M.J.; Lee, H.J.; Lee, I.A.; Kim, I.Y.; Lim, S.K.; Cho, H.A.; Kim, J.S. Preparation, of pH-sensitive, long-circulating and EGFRtargeted immunoliposomes. Arch. Pharm. Res., 2008, 31, 539-546.
86. Kim, I.Y.; Kang, Y.S.; Lee, D.S.; Park, H.J.; Choi, E.K.; Oh, Y.K.; Son, H.J.; Kim, J.S. Antitumor activity of EGFR targeted pHsensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J. Control. Release, 2009, 140, 55-60.
87. Simard, P.; Leroux, J.C. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells. Int. J. Pharm., 2009, 381, 86-96.
88. Hauck, M.; Coffin, D.; Dodge, R.; Dewhirst, M.; Mitchell, J.; Zalutsky, M.A. A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumor tumour interstitial blood pressure. Int. J. Hyperth., 1997, 13, 307-316.
89. Gaber, M.H.; Wu, N.Z.; Hong, K.; Huang, S.K.; Dewhirst, M.W.; Papahadjopoulos, D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int. J. Radiat. Oncol. Biol. Phys., 1996, 36, 1177-1187.
90. Dewhirst, M.W.; Prosnitz, L.; Thrall, D.; Prescott, D.; Clegg, S.; Charles, C.; MacFall, J.; Rosner, G.; Samulski, T.; Gillette, E.; LaRue, S. Hyperthermis treatment of malignant diseases: current status and a view toward the future. Semin. Oncol., 1997, 24, 616-625.
91. Kong, G.; Dewhirst, M.W. Hyperthermia and liposomes. Int. J. Hyperther., 1999, 15, 345-370.
92. Kong, G.; Braun, R.D.; Dewhirst, M.W. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res., 2001, 60, 4440-4445.
93. Needham, D.; Dewhirst, M.W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv. Drug Deliv. Rev., 2001, 53, 285-305.
94. Kong, G.; Anyarambhatla, G.; Petros, W.P.; Braun, R.D.; Colvin, O.M.; Needham, D.; Dewhirst, M.W. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res., 2000, 60, 6950-6957.
95. Zhu, L., Huo, Z., Wang, L., Tong, X., Xiao, Y., Ni, K. Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. Int. J. Pharm., 2009, 370, 136-143.
96. Kono, K. Thermosensitive polymer-modified liposomes. Adv. Drug Deliv. Rev., 2001, 53, 307-319.
97. Shen, Z.; Wei, W.; Zhao, Y.; Ma, G.; Dobashi, T.; Maki, Y.; Su, Z.; Wan, J. Thermosensitive polymer-conjugated albumin nanospheres as thermal targeting anti-cancer drug carrier. Eur. J. Pharm. Sci., 2008, 35, 271-282.
98. Purushotham, S.; Ramanujan, R.V. Thermoresponsive magnetic composite nanomaterials for multimodal cancer therapy. Acta Biomater., 2010, 6, 502-510.
99. Zhang, J.; Misra, R.D.K. Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: Core-shell nanoparticle carrier and drug release response Acta Biomater., 2007, 3, 838-850.
100. Ang, K.L.; Venkatraman, S.; Ramanujan, R.V. Magnetic PNIPA hydrogels for hyperthermia applications in cancer therapy. Mater. Sci. Eng. C, 2007, 27, 347-351.
101. Chan, D.C.F.; Kirpotin, D.B.; Bunn Jr.P.A. Synthesis and evaluation of colloidal magnetic iron oxides for the site-specific radiofrequency-induced hyperthermia of cancer. J. Magn. Magn. Mater., 1993, 122, 374-378.
102. Tashjian, J.A.; Dewhirst, M.W.; Needham, D.; Viglianti, B.L. Rationale for and measurement of liposomal drug delivery with hyperthermia using non-invasive imaging techniques. Int. J. Hyperthermia, 2008, 24, 79-90.
103. Kallumadil, M.; Tada, M.; Nakagawa, T.; Abe, M.; Southern, P.; Pankhurst, Q.A. Suitability of commercial colloids for magnetic hyperthermia. J. Magn. Magn. Mater., 2009, 321, 1509-1513.
104. Gupta, A.K.; Gupta, M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials, 2005, 26, 3995-4021.
105. Laurent, S.; Forge, D.; Port, M.; Roch, A.; Robic, C.; Elst, L.V.; Muller, R.N. Magnetic iron oxide nanoparticles: Synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem. Rev., 2008, 108, 2064-2110.
106. Huber, D.L. Synthesis, properties, and applications of iron nanoparticles. Small, 2005, 1, 482-501.
107. Ito, A.; Shinkai, M.; Honda, H.; Kobayashi, T. Medical application of functionalized magnetic nanoparticles. J. Biosci. Bioengin., 2005, 100, 1-11.
108. Steinkea, F.; Andräa, W.; Heidec, R.; Wernera, C.; Bellemann, M.E. Rotating magnetic macrospheres as heating mechanism for remote controlled drug release. J. Magn. Magn. Mater., 2007, 311, 216-218.
109. Hergt, R.; Dutz, S.; Müller, R.; Zeisberger, M. Magnetic particle hyperthermia: Nanoparticle magnetism and materials development for cancer therapy. J. Phys. Cond. Mater., 2006, 18, S2919-S2934.
110. Tanaka, K.; Ito, A.; Kobayashi, T.; Kawamura, T.; Shimada, S.; Matsumoto, K.; Saida, T.; Honda, H. Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma. J. Biosci. Bioeng., 2005, 100, 112-115.
111. Glöckl, G.; Hergt, R.; Zeisberger, M.; Dutz, S.; Nagel, S. Weitschies, W. The effect of field parameters, nanoparticles properties and immobilization on the specific heating power in magnetic particle hyperthermia J. Phys. Cond. Matter. 2006, 18, S2935-S2950.
112. Ciofani, G.; Riggio, C.; Raffa, V.; Menciassi, A.; Cuschieri, A. A bi-modal approach against cancer: Magnetic alginate nanoparticles for combined chemotherapy and hyperthermia. Med. Hypotheses, 2009, 73, 80-82.
113. Arias, J.L.; Galllardo, V.; Gómez-Lopera, S.A.; Plaza, R.C.; Delgado, A.V. Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J. Control. Release, 2001, 77, 309-321.
114. Závišová, V.; Koneracká, M.; Múčková, M.; Kopčanský, P.; Tomašovičová, N.; Lancz, G.; Timko, M.; Pätoprstá, B.; Bartoš, P.; Fabián, M. Synthesis and characterization of polymeric nanospheres with the anticancer drug paclitaxel and magnetic particles. J. Magn. Magn. Mater., 2009, 321, 1613-1616.
115. Fernández-Pacheco, R.; Marquina, C.; Valdivia, J.G.; Gutiérrez, M.; Romero, M.S.; Cornudella, R.; Laborda, A.; Viloria, A.; Higuera, T.; García, A.; García de Jalón, J.A.; Ibarra, M.R. Magnetic nanoparticles for local drug delivery using magnetic implants. J. Magn. Magn. Mater., 2007, 311, 318-322.
116. Rosengart, A.J.; Kaminski, M.D.; Chen, H.; Caviness, P.L.; Ebner, A.D.; Ritter, J.A. Magnetizable implants and functionalized magnetic carriers: A novel approach for noninvasive yet targeted drug delivery. J. Magn. Magn. Mater., 2005, 293, 633-638.
117. Yellen, B.B.; Forbes, Z.G.; Halverson, D.S.; Fridman, G.; Barbee, K.A.; Chorny, M.; Levy, R.; Friedman, G. Targeted drug delivery to magnetic implants for therapeutic applications. J. Magn. Magn. Mater., 2005, 293, 647-654.
118. Lin, J.J.; Chen, J.S.; Huang, S.J.; Ko, J.H.; Wang, Y.M.; Chen, T.L.; Wang, L.F. Folic acid-Pluronic F127 magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications. Biomaterials, 2009, 30, 5114-5124.
119. Tietze, R.; Jurgons, R.; Lyer, S.; Schreiber, E.; Wiekhorst, F.; Eberbeck, D.; Richter, H.; Steinhoff, U.; Trahms, L.; Alexiou, C. Quantification of drug-loaded magnetic nanoparticles in rabbit liver and tumor after in vivo administration J. Magn. Magn. Mater., 2009, 321, 1465-1468.
120. Reddy, G.R.; Bhojani, M.S.; McConville, P.; Moody, J.; Moffat, B.A.; Hall, D.E.; Kim, G.; Koo, Y.E.L.; Woolliscroft, M.J.; Sugai, J.V.; Johnson, T.D.; Philbert, M.A.; Kopelman, R.; Rehemtulla, A.; Ross, B.D. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin. Cancer Res., 2006, 12, 6677-6686.
121. Zhang, C.F.; Jugold, M.; Woenne, E.C.; Lammers, T.; Morgenstern, B.; Mueller, M.M.; Zentgraf, H.; Bock, M.; Eisenhut, M.; Semmler, W.; Kiessling, F. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res., 2007, 67, 1555-1562.
122. Bisby, R.H.; Mead, C.; Morgan, C.G. Active uptake of drugs into photosensitive liposomes and rapid release on UV photolysis. Photochem. Photobiol., 2000, 72, 57-61.
123. Shum, P.; Kim, J.M.; Thompson, D.H. Phototriggering of liposomal drug delivery systems. Adv. Drug Deliv. Rev., 2001, 53, 273-284.
124. Rapoport, N.; Christensen, D.; Fein, H.D.; Barrows, L.; Gao, Z. Ultrasound-triggered drug targeting to tumors in vitro and in vivo. Ultrasonics, 2004, 42, 943-950.
125. Gao, Z.; Fein, H.D.; Rapoport, N. Ultrasound-enhanced tumour targeting of polymeric micellar drug carrier. Mol. Pharm., 2004, 1, 317-330.
126. Larina, I.V.; Evers, B.M.; Ashitkov, T.V.; Bartels, C.; Larin, K.V.; Esenaliev, R.O. Enhancement of drug delivery in tumors by using interaction of nanoparticles with ultrasound radiation. Technol. Cancer. Res. Treat., 2005, 4, 217-226.
127. Schroeder, A.; Honen, R.; Turjeman, K.; Gabizon, A.; Kost, J.; Barenholz, Y. Ultrasound triggered release of cisplatin from liposomes in murine tumors. J. Control. Release, 2009, 137, 63-68.
128. Meers, P. Enzyme-activated targeting of liposomes. Adv. Drug Deliv. Rev., 2001, 53, 265-272.
129. Andresen, T.L.; Davidsen, J.; Begtrup, M.; Mouritsen, O.G.; Jørgensen, K. Enzymatic release of anti-tumor ether lipids by specific phospholipase A2 activation of novel liposome-forming prodrugs. J. Med. Chem., 2004, 47, 1694-1703.
130. Andresen, T.L.; Jensen, S.S.; Kaasgaard, T.; Jørgensen, K. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2. Curr. Drug Deliv., 2005, 2, 353-362.
131. Davis, S.C.; Szoka, F.C. Cholesterol phosphate derivatives: synthesis and incorporation into a phosphatase and calciumsensative triggered release liposome. Bioconj. Chem., 1998, 9, 783-792.
132. Zhang, Z.Y.; Shum, P.; Yates, M.; Messersmith, P.B.; Thompson, D.H. Formation of fibrinogen-based hydrogels using phototriggerable diplasmalogen liposomes. Bioconj. Chem., 2002, 13, 640-646.
133. Villar, A.V.; Alonso, A.; Goni, F.M. Leaky vesicle fusion induced by phosphatydilinositol-specific phospholipase C: observation of mixing of vesicular inner monolayers. Biochemistry, 2000, 39, 14012-14018.
134. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev., 2002, 2, 48-58.
135. Jabr-Milane, L.S.; van Vlerken, L.E.; Yadav, S.; Amiji, M.M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev., 2008, 34, 592-602.
136. Batrakova, E.V.; Kabanov, A.V. Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control. Release, 2008, 130, 98-106.
137. Sharma, A.K.; Zhang, L.; Li, S.; Kelly, D.L.; Alakhov, V.Y.; Batrakova, E.V.; Kabanov, A.V. Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. J. Control. Release, 2008, 131, 220-227.
138. Wu, J.; Lu, Y.; Lee, A.; Pan, X.; Yang, X.; Zhao, X.; Lee, R.J. Reversal of multidrug resistance by transferrin-conjugated liposomes coencapsulating doxorubicin and verapamil J. Pharm. Pharm. Sci., 2007, 10, 350-357.
139. Patil, Y.; Sadhukha, T.; Ma, L.; Panyam, J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release, 2009, 136, 21-29.
140. Pakunlu, R.I.; Wang, Y.; Saad, M.; Khandare, J.J.; Starovoytov, V.; Minko, T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J. Control. Release,2006, 114, 153-162.
141. Suzuki, S.; Inoue, K.; Hongoh, A.; Hashimoto, Y.; Yamazoe, Y. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor. Br. J. Cancer, 1997, 76, 83-89.
142. Mamot, C.; Drummond, D.C.; Hong, K.; Kirpotin, D.B.; Park, J.W. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist. Updates, 2003, 6, 271-279.
143. Matsuo, H.; Wakasugi, M.; Takanaga, H.; Ohtani, H.; Naito, M.; Tsuruo, T.; Sawada, Y. Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein J.Control. Release, 2001, 77, 77-86.
144. Pulkkinen, M.; Pikkarainen, J.; Wirth, T.; Tarvainen, T.; Haapaaho, V.; Korhonen, H.; Seppälä, J.; Järvinen, K. Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: formulation development and in vitro anticancer activity. Eur. J. Pharm. Biopharm., 2008, 70, 66-74.
145. van Verklen, L.E.; Duan, Z.; Seiden, M.V.; Amiji, M.M. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res., 2007, 67, 4843-4850.
146. Lee, E.S.; Na, K.; Bae, Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J.Control. Release, 2005, 103, 405-418.
147. Lynch, I.; Dawson, K.A. Protein-nanoparticle interactions. Nano Today, 2008, 3, 40-47.
148. Shubayev, V.I.; Pisanic II, T.R.; Jin, S. Magnetic nanoparticles for theragnostics. Adv. Drug Deliv. Rev., 2009, 61, 467-477.
149. Grainger, D.W. Nanotoxicity assessment: All small talk? Adv.Drug Deliv. Rev., 2009, 61, 419-421.
150. Fischer, H.C.; Chan, W.C.W. Nanotoxicity: the growing need for in vivo study. Curr. Opin. Biotechnol., 2007, 18, 565-571.
151. Maaßen, S.; Fattal, E.; Müller, R.H.; Couvreur, P. Cell culture for the assessment of toxicity and uptake of polymeric particulate drug carriers S.T.P. Pharma Sci., 1993, 3, 11-22.
152. Schütt, W.; Grüttner, C.; Häfeli, U.; Zborowski, M.; Teller, J.; Putzar, H.; Schümichen, C. Applications of magnetic targeting in diagnosis and therapy - possibilities and limitations. A minireview. Hybridoma, 1997, 16, 109-117.
153. Arruebo, M.; Fernández-Pacheco, R.; Ibarra, M.R.; Santamaría, J. Magnetic nanoparticles for drug delivery. Nano Today, 2007, 2, 22-32.
154. Karlsson, H.L.; Gustafsson, J.; Cronholm, P.; Möller, L. Sizedependent toxicity of metal oxide particles - A comparison between nano- and micrometer size. Toxicol. Lett., 2009, 188, 112-118.
155. Müller, R.H.; Maaßen, S.; Weyhers, H.; Specht, F.; Lucks, J.S. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles Int. J. Pharm., 1996, 138, 85-94.
156. Lübbe, A.S.; Bergemann, C.; Riess, H.; Schriever, F.; Reichardt, P.; Possinger, K.; Matthias, M.; Dörken, B.; Herrmann, F.; Gürtler, R.; Hohenberger, P.; Haas, N.; Sohr, R.; Sander, B.; Lemke, A.J.; Ohlendorf, D.; Huhnt, W.; Huhn, D. Clinical experiences with magnetic drug targeting: A phase I study with 4́-epidoxorubicin in 14 patients with advanced solid tumors Cancer Res., 1996, 56, 4686-4693.
157. Lübbe, A.S.; Bergemann, C.; Huhnt, W.; Fricke, T.; Riess, H.; Brock, J.W.; Huhn, D. Preclinical experiences with magnetic drug targeting: Tolerance and efficacy Cancer Res., 1996, 56, 4694-4701.
158. Sunderland, C.J.; Steiert, M.; Talmadge, J.E.; Derfus, A.M.; Barry, S.E. Targeted nanoparticles for detecting and treating cancer. Drug Develop. Res., 2006, 67, 70-93.
159. Ibrahim, A.; Couvreur, P.; Roland, M.; Speiser, P. New magnetic drug carrier. J. Pharm. Pharmacol., 1983, 35, 59-61.